ClinicalTrials.gg
Active, not recruitingNCT04005339Updated Oct 27, 2026Results posted

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

A Phase 2 interventional study of Nanoliposomal Irinotecan and Leucovorin in Advanced Biliary Tract Cancer, sponsored by Georgetown University. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Georgetown University · Phase 2, Interventional, and Treatment

How we know

Updated Oct 27, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing leucovorin in Biliary Tract Neoplasms — 2 open to participants now, 3 under way, none of them phase 3. Leucovorin · Biliary Tract Neoplasms.

Enrollment
4th of 10
48 · median 36
Started
2019
with 3 others
Phase 2
9 of 10
2 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Georgetown University

Among the 10 studies testing leucovorin in Biliary Tract Neoplasms, this one is the 4th largest by enrollment, is one of 4 that started in 2019, is one of 9 in phase 2, and was the 8th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

2 of the 10 studies testing leucovorin in Biliary Tract Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About leucovorin

Leucovorin: first FDA approval 1952 (LEUCOVORIN CALCIUM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing leucovorin in Biliary Tract Neoplasms, or all of them as a file.
02

Study summary

This is a study to evaluate the clinical activity of the combination of fluorouracil, leucovorin, and nanoliposomal irinotecan as second-line treatment in patients with advanced biliary tract cancers following gemcitabine and platinum chemotherapy.

Read the detailed description

This is a single arm, open label, multicenter phase II study to evaluate the clinical activity of the combination of fluorouracil, leucovorin, and nanoliposomal irinotecan as second-line treatment in patients with advanced biliary tract cancers following gemcitabine and platinum chemotherapy. Patients with advanced biliary tract cancers who have adequate performance status and adequate hepatic and renal function will be eligible. Patients may have received adjuvant chemotherapy and/or radiation therapy prior to enrolling in the trial, but a minimum of 6 months between adjuvant chemotherapy and this current therapy are required. Patients may continue on study as long as they are tolerating treatment and do not have progression of disease by RECIST v1.1 criteria. Response assessments will occur using imaging (CT or MRI) every 8 weeks.

03

Conditions studied

  • Advanced Biliary Tract Cancer

Keywords

  • Advanced Biliary Tract Cancer
  • Biliary Tract Cancer
  • GI Cancer
  • Biliary Cancer
  • NAPOLI-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -confirmed biliary tract cancer (cholangiocarcinoma or gallbladder adenocarcinoma), unresectable or
  • Disease progression on or intolerance of gemcitabine- and platinum-based chemotherapy
  • No more than 1 for unresectable or metastatic disease ( therapy does not count)
  • by v1.1 criteria
  • performance status of 0-1
  • At least 18 years of age
  • -positive patients are eligible provided: Stable HAART regimen, No concurrent prophylactic antibiotics or antifungals, and above 250 and undetectable viral load
  • Adequate bone marrow, hepatic, and renal function
  • Consent to access archived tumor tissue if available (available tissue is not required for enrollment)

Exclusion criteria

Exclusion Criteria:

  • Ampullary adenocarcinoma
  • Woman who are pregnant or breastfeeding
  • Anti-cancer treatment within 3 weeks prior to enrollment
  • Prior irinotecan or nanoliposomal irinotecan
  • Central nervous system unless stable for at least 4 weeks and at least 2 weeks off
  • Exposure to a strong inducer, strong CYP3A4 inhibitor, or strong UGT1A1 inhibitor within 2 weeks of study start
  • Known concurrent or other malignancy within 3 years except for non-melanomatous skin cancers, prostate or cervical cancers following curative therapy, or superficial bladder cancer
  • Bowel obstruction
  • Allergy or to fluoropyrimidines, irinotecan, or nanoliposomal irinotecan
  • liver disease: Patients with resolved infection are eligible if HBsAg testing is negative; Patients with resolved infection are eligible if viral RNA PCR is negative
  • Severe infections within 4 weeks prior to enrollment
  • Major surgery within 4 weeks prior to enrollment
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Single Arm

    Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days. Leucovorin 400 mg/ IV over 30 minutes, every 14 days. Fluorouracil 2,400 mg/m IV over 46 hours.

    Drug: Nanoliposomal Irinotecan · Drug: Leucovorin · Drug: Fluorouracil

Interventions

06

What researchers measure

Primary outcomes

  1. The Efficacy of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Advanced Biliary Tract Cancers Following Progression on or Intolerance of Gemcitabine and Platinum Chemotherapy.

    The number of participants with no evidence of disease progression (PD) at 4 months, as measured by RECIST v1.1 criteria.

    Time frame: 4 months

Secondary outcomes

  1. Overall Response Rate (ORR).

    The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of best overall response rate (ORR).

    Time frame: 6 months

  2. Median Progression-free Survival (mPFS).

    The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of median progression-free survival (mPFS).

    Time frame: 6 months

  3. Median Overall Survival (mOS).

    The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of median overall survival (mOS).

    Time frame: 6 months

  4. Median Time to Disease Progression (mTTP).

    The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of median time to disease progression (mTTP).

    Time frame: 6 months

  5. Disease Control Rate (DCR).

    The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of disease control rate (DCR).

    Time frame: 6 months

  6. Median Duration of Disease Control (DDC).

    The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of median duration of disease control (DDC).

    Time frame: 6 months

  7. Maximum Change in Tumor Marker, CA19-9.

    The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of maximum change in tumor marker, CA19-9.

    Time frame: 6 months

Other outcomes

  1. Blood for the Analysis of Circulating Tumor DNA as a Surrogate Marker of Disease Burden.

    Correlation of dynamics of circulating tumor DNA change compared with change in CA19-9.

    Time frame: 6 months

  2. Archived Tumor Tissue Using Next-generation Sequencing (NGS) and Immunohistochemistry (IHC) in Order to Elucidate Potential Mutational Biomarkers Predictive of Response to Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan.

    Correlation of tumor genetic mutations and protein expression levels with progression-free survival.

    Time frame: 6 months

07

Results

Posted Oct 27, 2026

Participant flow

48 subjects were recruited from 4 academic cancer centers in the United States in Washington, DC, St. Louis, Missouri, Indianapolis, Indiana, and New York, New York. The first stage recruited until there were 19 evaluable subjects at 4 month. If 6 or more (out of 19 evaluable) patients were progression free the trial continued with an additional 20 evaluable patients being enrolled during the second stage (for a total of 39 evaluable patients).

Participant flow — Overall Study
MilestoneSingle Arm
Started48
Per protocol - month 439
Completed0
Not completed48
Withdrew: Adverse event8
Withdrew: Alternative therapy1
Withdrew: Disease progression32
Withdrew: Other complicating disease1
Withdrew: Withdrawal by subject2
Withdrew: Physician decision4

Outcome measures

PrimaryThe Efficacy of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Advanced Biliary Tract Cancers Following Progression on or Intolerance of Gemcitabine and Platinum Chemotherapy.

The number of participants with no evidence of disease progression (PD) at 4 months, as measured by RECIST v1.1 criteria.

Time frame:
4 months
Reported as:
Count of participants · Participants
The Efficacy of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Advanced Biliary Tract Cancers Following Progression on or Intolerance of Gemcitabine and Platinum Chemotherapy.
ParticipantsSingle Arm
The Efficacy of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Advanced Biliary Tract Cancers Following Progression on or Intolerance of Gemcitabine and Platinum Chemotherapy.19
SecondaryOverall Response Rate (ORR).

The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of best overall response rate (ORR).

Time frame:
6 months

Results for this outcome have not been posted.

SecondaryMedian Progression-free Survival (mPFS).

The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of median progression-free survival (mPFS).

Time frame:
6 months

Results for this outcome have not been posted.

SecondaryMedian Overall Survival (mOS).

The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of median overall survival (mOS).

Time frame:
6 months

Results for this outcome have not been posted.

SecondaryMedian Time to Disease Progression (mTTP).

The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of median time to disease progression (mTTP).

Time frame:
6 months

Results for this outcome have not been posted.

SecondaryDisease Control Rate (DCR).

The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of disease control rate (DCR).

Time frame:
6 months

Results for this outcome have not been posted.

SecondaryMedian Duration of Disease Control (DDC).

The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of median duration of disease control (DDC).

Time frame:
6 months

Results for this outcome have not been posted.

SecondaryMaximum Change in Tumor Marker, CA19-9.

The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy measured in terms of maximum change in tumor marker, CA19-9.

Time frame:
6 months

Results for this outcome have not been posted.

Other pre-specifiedBlood for the Analysis of Circulating Tumor DNA as a Surrogate Marker of Disease Burden.

Correlation of dynamics of circulating tumor DNA change compared with change in CA19-9.

Time frame:
6 months

Results for this outcome have not been posted.

Other pre-specifiedArchived Tumor Tissue Using Next-generation Sequencing (NGS) and Immunohistochemistry (IHC) in Order to Elucidate Potential Mutational Biomarkers Predictive of Response to Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan.

Correlation of tumor genetic mutations and protein expression levels with progression-free survival.

Time frame:
6 months

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were collected per protocol froom the time of study drug administration until 30 days following discontinuation of study drug administration, up to 26 months, All Cause Mortality was collected from time of study drug administration through death, for up to 2 years after discontinuation of treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Arm38/48 (79.2%)33/48 (68.8%)47/48 (97.9%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventSingle Arm
SepsisInfections and infestations7/48
DiarrheaGastrointestinal disorders4/48
Acute kidney injuryRenal and urinary disorders4/48
Abdominal painGastrointestinal disorders3/48
Febrile neutropeniaBlood and lymphatic system disorders2/48
NauseaGastrointestinal disorders2/48
Small intestinal obstructionGastrointestinal disorders2/48
VomitingGastrointestinal disorders2/48
FatigueGeneral disorders2/48
Infections and infestations - Other, specify:Infections and infestations2/48
Most frequent other events
Showing 10 of 110
Most frequent other events
EventSingle Arm
DiarrheaGastrointestinal disorders33/48
NauseaGastrointestinal disorders32/48
FatigueGeneral disorders29/48
AnorexiaMetabolism and nutrition disorders25/48
Abdominal painGastrointestinal disorders17/48
VomitingGastrointestinal disorders17/48
AnemiaBlood and lymphatic system disorders16/48
AlopeciaSkin and subcutaneous tissue disorders14/48
Edema limbsGeneral disorders12/48
Neutrophil count decreasedInvestigations12/48

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Single Arm
<=18 years0
Between 18 and 65 years25
>=65 years23
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm
Female33
Male15
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single Arm
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American9
White32
More than one race2
Unknown or Not Reported3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single Arm
Hispanic or Latino3
Not Hispanic or Latino42
Unknown or Not Reported3
08

Study locations

4 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Sep 2025, 73 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 101 non-industry phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 60. This study's 73 months is above that.

Counting every sponsor, half of 132 studies reached it within 39 months; a quarter within 29 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2019
First posted
Jul 2, 2019
StartActual
Jul 29, 2019
Primary completionActual
Sep 3, 2025
CompletionEst.
Dec 31, 2026
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedThe efficacyEfficacy of fluorouracilFluorouracil, leucovorinLeucovorin, and nanoliposomal irinotecanNanoliposomal Irinotecan in advanced biliary tract cancers following progressionAdvanced Biliary Tract Cancers Following Progression on or intoleranceIntolerance of gemcitabineGemcitabine and platinum chemotherapyPlatinum Chemotherapy.Time frame: 4 months
Oct 27, 2026
Documents
Secondary outcomes
9 edited
What changed in the outcomes
  • EditedOverall response rateResponse Rate (ORR).Time frame: 6 months
  • EditedMedian progressionProgression-free survivalSurvival (mPFS).Time frame: 6 months
  • EditedMedian overall survivalOverall Survival (mOS).Time frame: 6 months
  • EditedMedian timeTime to disease progressionDisease Progression (mTTP).Time frame: 6 months
  • EditedDisease control rateControl Rate (DCR).Time frame: 6 months
  • EditedMedian durationDuration of disease controlDisease Control (DDC).Time frame: 6 months
  • EditedMaximum changeChange in tumor markerTumor Marker, CA19-9.Time frame: 6 months
  • Editedother outcomeBlood for the analysisAnalysis of circulating tumorCirculating Tumor DNA as a surrogate markerSurrogate Marker of disease burdenDisease Burden.Time frame: 6 months
  • Editedother outcomeArchived tumor tissue using nextTumor Tissue Using Next-generation sequencingSequencing (NGS) and immunohistochemistryImmunohistochemistry (IHC) in orderOrder to elucidate potential mutational biomarkers predictiveElucidate Potential Mutational Biomarkers Predictive of responseResponse to fluorouracilFluorouracil, leucovorinLeucovorin, and nanoliposomal irinotecanNanoliposomal Irinotecan.Time frame: 6 months
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedThe efficacyEfficacy of fluorouracilFluorouracil, leucovorinLeucovorin, and nanoliposomal irinotecanNanoliposomal Irinotecan in advanced biliary tract cancers following progressionAdvanced Biliary Tract Cancers Following Progression on or intoleranceIntolerance of gemcitabineGemcitabine and platinum chemotherapyPlatinum Chemotherapy.Time frame: 4 months
    Secondary outcomes 9 edited
    What changed in the outcomes
    • EditedOverall response rateResponse Rate (ORR).Time frame: 6 months
    • EditedMedian progressionProgression-free survivalSurvival (mPFS).Time frame: 6 months
    • EditedMedian overall survivalOverall Survival (mOS).Time frame: 6 months
    • EditedMedian timeTime to disease progressionDisease Progression (mTTP).Time frame: 6 months
    • EditedDisease control rateControl Rate (DCR).Time frame: 6 months
    • EditedMedian durationDuration of disease controlDisease Control (DDC).Time frame: 6 months
    • EditedMaximum changeChange in tumor markerTumor Marker, CA19-9.Time frame: 6 months
    • Editedother outcomeBlood for the analysisAnalysis of circulating tumorCirculating Tumor DNA as a surrogate markerSurrogate Marker of disease burdenDisease Burden.Time frame: 6 months
    • Editedother outcomeArchived tumor tissue using nextTumor Tissue Using Next-generation sequencingSequencing (NGS) and immunohistochemistryImmunohistochemistry (IHC) in orderOrder to elucidate potential mutational biomarkers predictiveElucidate Potential Mutational Biomarkers Predictive of responseResponse to fluorouracilFluorouracil, leucovorinLeucovorin, and nanoliposomal irinotecanNanoliposomal Irinotecan.Time frame: 6 months

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04005339
Collaborators
Ipsen
Responsible party
Sponsor
First posted
Jul 2, 2019
Start date
Jul 29, 2019
Primary completion
Sep 3, 2025
Completion
Dec 31, 2026 (estimated)
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

Benjamin Weinberg, MD
study chair · Georgetown University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irinotecan sucrosofate · Leucovorin · Fluorouracil

Start the discussion